

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

August 12th, 2019

Re: Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in connection with the disposal of equity shares of Fortis Healthcare Limited.

Dear Sir,

This is to inform you that the entities named hereinafter, have sold equity shares for *Fortis Healthcare Limited* ("**Company**") on August 8th, 2019 by way of an open market sale. The details of the sale are as follows:

Sr. No.	Seller	No. of equity shares sold
1.	Jupiter Asian Fund (SEBI registered FII Sub-Account No. INUKFP242316)	33,229 equity shares constituting 0.03% of the voting rights of the Company.
2.	Emirates Emerging Market (SEBI registered FII – Registration No. INJEFP158115)	13,054 equity shares constituting 0.03% of the voting rights of the Company.
3.	Omnis GEM Portfolio (SEBI registered FII – Registration No. INUKFP019715)	188,717 equity shares constituting 0.03% of the voting rights of the Company.

Enclosed is the copy of the disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in connection with the disposal. We request you to kindly take the same on record.

The disclosure has been emailed to the following ids:

corp.relations@bseindia.com

The originals are being couriered from London and thus will reach your office in due time.

We have also made a requisite disclosure to Fortis Healthcare Ltd and NSE Ltd. Request you to kindly acknowledge the receipt of this letter and the disclosure.

Yours sincerely,

Jupiter Asian Fund (SEBI registered FII
Sub-Account No. INUKFP242316)



Jupiter Asset Management Ltd

Authorised Signatory (Investment
Manager)

Place: London

Date: August 12th, 2019

Emirates Emerging Market (SEBI
registered FII – Registration No.
INJEFP158115)



Jupiter Asset Management Ltd

Authorised Signatory (Investment
Manager)

Place: London

Date: August 12th, 2019

Omnis GEM Portfolio (SEBI registered FII –
Registration No. INUKFP019715)



Jupiter Asset Management Ltd

Authorised Signatory (Investment
Manager)

Place: London

Date: August 12th, 2019

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Fortis Healthcare Limited		
Name(s) of the seller and Persons Acting in Concert (PAC) with the seller	<u>Seller:</u> Jupiter Asset Management Limited ¹ (on behalf of its clients).		
Whether the seller belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	<ul style="list-style-type: none"> • Bombay Stock Exchange Limited • National Stock Exchange of India Limited 		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition/disposal under consideration, holding of seller of:			
a) Shares carrying voting rights	NIL	NIL	NIL
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)	NIL	NIL	NIL

¹ Note: Jupiter Asset Management Limited (i.e. the “**Seller/ JAM**”) acts as the non-exclusive investment manager for various independent funds (“**Funds**”), and independently exercises all the voting rights in respect of the equity shares of the Target Company acquired by the aforesaid funds. Prior to the disposal in question: (a) JAM had submitted a disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on August 21, 2018, disclosing the acquisition of 5.05% voting rights in the Target Company pursuant to acquisition of equity shares of the Target Company by various Funds; and (b) between August 21, 2018 and August 07, 2019, the Funds disposed-off equity shares of the Target Company in various tranches.

As of August 07, 2019, the Funds held 3.06% equity shares of the Target and correspondingly, JAM held 3.06% voting rights in the Target. The following disposals were made by three Funds on August 08, 2019: (i) 33,229 equity shares of the Target Company by Jupiter Asian Fund (INUKFP242316); (ii) 13,054 equity shares of the Target Company by Emirates Emerging Market (INJEFP158115); (iii) 188,717 equity shares of the Target Company Omnis GEM Portfolio (INUKFP019715). Pursuant to the aforesaid disposal, JAM’s total voting rights in the Target Company has been reduced to 3.03%.

c) Voting rights (VR) otherwise than by equity shares	2,31,33,169	3.06%	3.06% ²
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
e) Total (a+b+c+d)	2,31,33,169	3.06%	3.06%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	NIL	NIL	NIL
b) VRs acquired /sold otherwise than by shares	2,35,000	0.03%	0.03% ³
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	NIL	NIL	NIL
d) Shares encumbered / invoked/released by the acquirer.	NIL	NIL	NIL
e) Total (a+b+c+/-d)	2,35,000	0.03%	0.03%
After the acquisition/sale, holding of seller of:			
a) Shares carrying voting rights	NIL	NIL	NIL
b) Shares encumbered with the acquirer	NIL	NIL	NIL
c) VRs otherwise than by equity shares	2,28,98,169	3.03%	3.03% ⁴

² **Note:** The aggregate voting rights of the Target Company which JAM holds (on behalf of all the Funds for which it acts as the investment manager), prior to the disposal in question, is 3.06%.

³ **Note:** The aggregate voting rights of the Target Company which JAM disposed-off (as explained above) is 0.03%.

⁴ **Note:** The aggregate voting rights of the Target Company which JAM holds (on behalf of all the Funds for which it acts as the investment manager), after the disposal in question, is 3.03%

d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
e) Total (a+b+c+d)	2,28,98,169	3.03%	3.03%
Mode of acquisition /sale (e.g. open market / off-market / public issue / rights issue /preferential allotment / inter-se transfer etc.)	Open Market		
Date of acquisition of sale of voting rights shares / or date of receipt of intimation of allotment of shares, whichever is applicable	August 8 th , 2019		
Equity share capital / total voting capital of the TC before the said acquisition /sale	754,958,148 equity shares, with each equity share having a face value of INR 10.		
Equity share capital/ total voting capital of the TC after the said acquisition /sale	754,958,148 equity shares, with each equity share having a face value of INR 10.		
Total diluted share/voting capital of the TC after the said acquisition /sale	754,958,148 equity shares, with each equity share having a face value of INR 10.		

Signature of the Seller / Authorised Signatory



Place: London, UK

Date: 12/8/19

Name: Sharon Kennedy

Title: Regulatory Reporting Manager

Place: London, UK

Date: 12th August, 2019

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.